{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:33Z","timestamp":1794047433897,"version":"4.8.0"},"reference-count":10,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.282587","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T04:05:32Z","timestamp":1680753932000},"page":"1988-1990","source":"Crossref","is-referenced-by-count":3,"title":["CAR T-cell therapy for triple-class exposed relapsed\/refractory multiple myeloma"],"prefix":"10.3324","volume":"108","author":[{"given":"Michele","family":"Cavo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"49905","doi-asserted-by":"crossref","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel). 2023; 15(5):1558.","DOI":"10.3390\/cancers15051558"},{"key":"49906","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"49907","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD Jr, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"49908","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"49909","doi-asserted-by":"crossref","unstructured":"Mateos MV, Weisel K, Martin T. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2023; 108(8):2192-2204.","DOI":"10.3324\/haematol.2022.280482"},{"key":"49910","doi-asserted-by":"crossref","unstructured":"Mateos MV, Weisel K, De Stefano V. LocoMMotion: a prospective, noninterventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376.","DOI":"10.1038\/s41375-022-01531-2"},{"key":"49911","doi-asserted-by":"crossref","unstructured":"Costa LJ, Lin Y, Cornell RF. Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022; 22(5):326-335.","DOI":"10.1016\/j.clml.2021.10.013"},{"key":"49912","doi-asserted-by":"crossref","unstructured":"Martin T, Krishnan A, Yong K. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem. 2021; 3(1):97-108.","DOI":"10.1002\/jha2.312"},{"key":"49913","doi-asserted-by":"crossref","unstructured":"Weisel K, Krishnan A, Schecter JM. Matching-adjusted indirect treatment comparison to assess the comparative eficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022; 22(9):690-701.","DOI":"10.1016\/j.clml.2022.04.025"},{"key":"49914","unstructured":"A study comparing JNJ-68284528, a CAR-T therapy directed against B-cell maturation antigen (BCMA), versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in participants with relapsed and lenalidomide-refractory multiple myeloma (CARTITUDE-4). ClinicalTrials.gov. Updated January 18. 2023."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282587\/75518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282587\/75862","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11045\/75518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:52Z","timestamp":1794045832000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282587","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}